Entyvio’s Effect in IBD Continues After Years of Treatment

Entyvio’s Effect in IBD Continues After Years of Treatment
Takeda recently published interim data showing that Entyvio (vedolizumab) treatment continues to be beneficial for people with ulcerative colitis or Crohn’s disease, whether or not they were treated with TNF-blockers at an earlier date. The study, “Long-term Efficacy of Vedolizumab for Ulcerative Colitis,” published in the Journal of Crohn’s and Colitis, also shows that patients who got better when Entyvio

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Great paper!
    This medication has revolutionized the RX of IBD, as we continue to observe deep remission in patients with longstanding disease who have failed other therapies.
    Novel treatment with other agents to provide non toxic cost effective therapy is warranted.

Leave a Comment

Your email address will not be published. Required fields are marked *